BioVie Inc. – NASDAQ:BIVI
BioVie stock price today
$1.59
-0.53
-25.35%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
BioVie stock price monthly change
+359.25%
month
BioVie stock price quarterly change
+359.25%
quarter
BioVie stock price yearly change
+67.72%
year
BioVie key metrics
Market Cap | 34.73M |
Enterprise value | 197.47M |
P/E | -5.1 |
EV/Sales | N/A |
EV/EBITDA | -5.33 |
Price/Sales | N/A |
Price/Book | 9.32 |
PEG ratio | -0.05 |
EPS | -1.1 |
Revenue | N/A |
EBITDA | -41.10M |
Income | -38.37M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioVie stock price history
BioVie stock forecast
BioVie financial statements
| Jun 2022 | 0 | -5.97M | |
|---|---|---|---|
| Mar 2023 | 0 | -15.22M | |
| Jun 2023 | 0 | -9.11M | |
| Mar 2024 | 0 | -8.06M |
| 2026 | 12.8M | -43.82M | -342.36% |
|---|---|---|---|
| 2027 | 367.50M | 140.65M | 38.27% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-04 | -0.50665 | -0.38 |
|---|---|---|
| 2023-02-10 | -0.9901 | -0.5 |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | 24.82% |
|---|---|
| 2021 | |
| 2022 | |
| 2023 | |
| 2024 |
| Dec 2022 | 47191968 | 21.12M | 44.76% |
|---|---|---|---|
| Mar 2023 | 45182696 | 23.46M | 51.93% |
| Jun 2023 | 35104730 | 19.76M | 56.3% |
| Mar 2024 | 31772861 | 12.84M | 40.43% |
| Jun 2022 | -5.86M | 0 | 0 |
|---|---|---|---|
| Mar 2023 | -11.73M | -12.50M | 9.76M |
| Jun 2023 | -11.28M | -1.79M | 1.26M |
| Mar 2024 | -5.85M | 0 | 15.97M |
BioVie alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 18 |
| Oct 2023 | 18 |
| Nov 2023 | 18 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 18 |
| Jul 2024 | 18 |
BioVie other data
1.58%
-2.91%
of BIVI is owned by hedge funds
23
-15
491.50K
-730.69K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 0 | 5000 |
| Jun 2023 | 0 | 5984 |
| Aug 2023 | 0 | 10805 |
| Sep 2023 | 0 | 8560 |
| Nov 2023 | 10000 | 0 |
| Dec 2023 | 0 | 75680 |
| Mar 2024 | 15000 | 0 |
| Patent |
|---|
Application Filling date: 22 May 2020 Issue date: 28 Jul 2022 |
Application Filling date: 18 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 9 Apr 2019 Issue date: 5 Dec 2019 |
| Insider | Compensation |
|---|---|
Mr. Jonathan M. Adams M.B.A., MBA (1963) Executive Vice President of Liver Disease Program | $267,200 |
Ms. Joanne Wendy Kim CPA (1955) Chief Financial Officer & Corporation Sec. | $120,620 |
BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value
BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade)
BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Benefit Investors
BioVie: Not Investible For Its Alzheimer's Program
BioVie Day And The Path Of Least Resistance To Approval In Alzheimer's
BioVie: Update On Alzheimer's And Parkinson's Programs, And Focus On Its Treatment For Refractory Ascites
BioVie: Quick Rise And Fall Of An Alzheimer's Disease Drug Developer
BioVie Inc: A Catalyst-Rich Year Ahead
BioVie: 9 Reasons For Enthusiasm
-
What's the price of BioVie stock today?
One share of BioVie stock can currently be purchased for approximately $1.59.
-
When is BioVie's next earnings date?
Unfortunately, BioVie's (BIVI) next earnings date is currently unknown.
-
Does BioVie pay dividends?
No, BioVie does not pay dividends.
-
How much money does BioVie make?
BioVie has a market capitalization of 34.73M. BioVie made a loss 32.12M US dollars in net income (profit) last year or -$0.5 on an earnings per share basis.
-
What is BioVie's stock symbol?
BioVie Inc. is traded on the NASDAQ under the ticker symbol "BIVI".
-
What is BioVie's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioVie?
Shares of BioVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioVie's key executives?
BioVie's management team includes the following people:
- Mr. Jonathan M. Adams M.B.A., MBA Executive Vice President of Liver Disease Program(age: 62, pay: $267,200)
- Ms. Joanne Wendy Kim CPA Chief Financial Officer & Corporation Sec.(age: 70, pay: $120,620)
-
How many employees does BioVie have?
As Jul 2024, BioVie employs 18 workers.
-
When BioVie went public?
BioVie Inc. is publicly traded company for more then 5 years since IPO on 18 Sep 2020.
-
What is BioVie's official website?
The official website for BioVie is bioviepharma.com.
-
Where are BioVie's headquarters?
BioVie is headquartered at 680 West Nye Lane, Carson City, NV.
-
How can i contact BioVie?
BioVie's mailing address is 680 West Nye Lane, Carson City, NV and company can be reached via phone at +7 758883162.
BioVie company profile:
BioVie Inc.
bioviepharma.comExchange:
NASDAQ
Full time employees:
14
Industry:
Biotechnology
Sector:
Healthcare
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
680 West Nye Lane
Carson City, NV 89703
Carson City, NV 89703
CIK: 0001580149
ISIN: US09074F2074
CUSIP: 09074F207
